Dr. Graeme Moyle discusses the impact of cardiometabolic health on women living with HIV and key considerations when reviewing their antiretroviral therapy (ARV)

DELSTRIGO® (doravirine/lamivudine/tenofovir disoproxil fumarate) Prescribing Information (United Kingdom) [External link]
PIFELTRO® (doravirine) Prescribing Information (United Kingdom) [External link]

PIFELTRO® (doravirine) 100 mg film-coated tablet is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older, weighing at least 35 kg, infected with HIV-1, without past or present evidence of resistance to the NNRTI class.

DELSTRIGO® (100 mg doravirine/300 mg lamivudine/300 mg tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil) is indicated for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine or tenofovir.

DELSTRIGO® is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg, who are infected with HIV-1, without the past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.

Please consult the SmPC for further information before making any prescribing decisions.

In this video Dr Graeme Moyle shares a case study examining the impact of cardiometabolic health of a women living with HIV and discussion points to consider when looking at reviewing her ARV therapy. This short video case study presentation aims to support your understanding of the metabolic effects of HIV and ageing on women living with HIV

Please note that this is one individual and cases may vary.

Filming fully organised and funded by MSD, including speaker’s honoraria. Views of the speaker are their own and do not represent the opinions of MSD.

This video is split into 2 parts, please watch Part 1 before watching Part 2.

Part 1

Part 2

For more information on doravirine and PLWH and Cardiometabolic risk.

Click here to know more

DELSTRIGO has been studied over 4 years in people living with HIV, 12 years and above

View clinical data

Supporting documentation

DELSTRIGO® Prescribing Information (United Kingdom) [External link]
PIFELTRO® Prescribing Information (United Kingdom) [External link]
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website